103 related articles for article (PubMed ID: 35094566)
1. Treatment patterns and economic burden among cervical and endometrial cancer patients newly initiating systemic therapy.
Kebede N; Shah R; Shah A; Corman S; Nwankwo C
Future Oncol; 2022 Mar; 18(8):953-964. PubMed ID: 35094566
[No Abstract] [Full Text] [Related]
2. Treatment patterns and economic burden among newly diagnosed cervical and endometrial cancer patients.
Nwankwo C; Shah R; Shah A; Corman S; Kebede N
Future Oncol; 2022 Mar; 18(8):965-977. PubMed ID: 35105169
[No Abstract] [Full Text] [Related]
3. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
[No Abstract] [Full Text] [Related]
4. Phase-specific and lifetime economic burden of cervical cancer and endometrial cancer in a commercially insured United States population.
Shah R; Corman S; Shah A; Kebede N; Nwankwo C
J Med Econ; 2021; 24(1):1221-1230. PubMed ID: 34686073
[TBL] [Abstract][Full Text] [Related]
5. Real-World Analysis of Treatment Patterns, Healthcare Utilization, Costs, and Mortality Among People with Biliary Tract Cancers in the USA.
Healey MJ; Seal B; Princic N; Black D; Malangone-Monaco E; Azad NS; Smoot RL
Adv Ther; 2022 Dec; 39(12):5530-5545. PubMed ID: 36241962
[TBL] [Abstract][Full Text] [Related]
6. Cost information of chemotherapy for cervical and endometrial cancer in Japan.
Kamijo Y; Ichikawa M
Jpn J Nurs Sci; 2014 Jul; 11(3):190-9. PubMed ID: 25065965
[TBL] [Abstract][Full Text] [Related]
7. Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Lam C; Diessner B; Andrade K; Stackland S; Park L; Mehta S; Lin F; Kwong WJ
J Comp Eff Res; 2024 Apr; 13(5):e230166. PubMed ID: 38647165
[No Abstract] [Full Text] [Related]
8. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
Kearney M; Thokagevistk K; Boutmy E; Bharmal M
J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
[TBL] [Abstract][Full Text] [Related]
9. Informing health policy in Japan: A mixed-model estimation to compare the cost of illness of cervical cancer and endometrial cancer.
Hayata E; Seto K; Kitazawa T; Matsumoto K; Morita M; Hasegawa T
J Obstet Gynaecol Res; 2016 Apr; 42(4):446-56. PubMed ID: 26712320
[TBL] [Abstract][Full Text] [Related]
10. The economic burden of end-of-life care in metastatic breast cancer.
Bramley T; Antao V; Lunacsek O; Hennenfent K; Masaquel A
J Med Econ; 2016 Nov; 19(11):1075-1080. PubMed ID: 27248201
[TBL] [Abstract][Full Text] [Related]
11. Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States.
Kobayashi M; Garside J; Nguyen J
J Health Econ Outcomes Res; 2023; 10(2):104-110. PubMed ID: 37954059
[No Abstract] [Full Text] [Related]
12. Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States.
Dacosta Byfield SA; Adejoro O; Copher R; Chatterjee D; Joshi PR; Worden FP
Adv Ther; 2019 Apr; 36(4):896-915. PubMed ID: 30820872
[TBL] [Abstract][Full Text] [Related]
13. Healthcare resource use in advanced prostate cancer patients treated with docetaxel.
Mehra M; Wu Y; Dhawan R
J Med Econ; 2012; 15(5):836-43. PubMed ID: 22463616
[TBL] [Abstract][Full Text] [Related]
14. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
[No Abstract] [Full Text] [Related]
15. Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases.
Dispenzieri A; Zonder J; Hoffman J; Wong SW; Liedtke M; Abonour R; D'Souza A; Lee C; Cote S; Potluri R; Ammann E; Tran N; Lam A; Nair S
Amyloid; 2023 Jun; 30(2):161-168. PubMed ID: 36282014
[TBL] [Abstract][Full Text] [Related]
16. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
[TBL] [Abstract][Full Text] [Related]
17. The Cost of Locally Advanced Cervical Cancer in Thailand: an Empirical Study for Economic Analysis.
Katanyoo K; Riewpaiboon A; Chaikledkaew U; Thavorncharoensap M
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3171-3179. PubMed ID: 34710993
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma.
Aly A; Malangone-Monaco E; Noxon V; Henriques C; Benavente F; Kim A
Curr Med Res Opin; 2020 Nov; 36(11):1813-1823. PubMed ID: 32969741
[TBL] [Abstract][Full Text] [Related]
19. Overall care cost comparison between robotic and laparoscopic surgery for endometrial and cervical cancer.
Desille-Gbaguidi H; Hebert T; Paternotte-Villemagne J; Gaborit C; Rush E; Body G
Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):348-52. PubMed ID: 24135382
[TBL] [Abstract][Full Text] [Related]
20. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
